...
首页> 外文期刊>Journal of Clinical Microbiology >Galactomannan testing for early diagnosis of Exserohilum rostratum infection
【24h】

Galactomannan testing for early diagnosis of Exserohilum rostratum infection

机译:

获取原文
获取原文并翻译 | 示例
           

摘要

E'xserohilum rostratum is the most common pathogen in the current U.S. outbreak of fungal central nervous system infection, septic arthritis, and localized spinal or paraspinal infections (1). Rapid laboratory diagnosis is urgently needed but is unfortunately still limited. Only 30 of the 372 case patient specimens sent to the Centers for Disease Control and Prevention (CDC) had PCR evidence supportive of fungal infection (1, 2). The 3-D-glu-can assay, which can detect (1,3)-beta-D-glucan, a major cell wall component of many fungi, was useful in culture-independent diagnosis of three patients who were potentially exposed to contaminated methylprednisolone and presented with findings suggestive of fungal central nervous system infection (3). The assay, however, has not been approved by the U.S. Food and Drug Administration (FDA) for use on cerebrospinal fluid (CSF) samples. Galactomannan is a major constituent of Aspergillus cell walls that is released during growth and can be detected by an FDA-approved immunoassay (4). Positive serum galactomannan antigen has also been reported during invasive infections by other fungi, such as Penicillium, Alternaria, Paecilomyces, Histoplasma, Geotrichum, Fusarium, and Cryptococcus species (5-10). We present a case of Exserohilum rostratum infection in which the serum galactomannan assay facilitated early diagnosis. A 44-year-old male with acute lymphoblastic leukemia who underwent allogeneic stem cell transplantation developed necrotic lesions in the nose and maxillary sinus. Biopsy showed angioinvasive brown-pigmented septate hyphae, and the culture was identified morphologically and by intergenic transcribed spacer (ITS) region and 28S ribosomal DNA sequences as Exserohilum rostratum. Treatment with intravenous amphotericin B deoxycholate at 1.5 mg/kg of body weight/day resulted in clinical improvement, and recovery followed engraftment. The serum galactomannan test was positive at presentation, thus driving early detection of invasive fungal disease. Galactomannan levels declined slowly under treatment (Table 1) but remained positive after neutrophil recovery. At the time of serum sample collection, the patient did not receive antibiotics, such as piperacillin-tazobactam, amoxicillin-clavu-lanate, or gluconate-containing Plasma-Lyte solutions, that could have caused false positivity in the galactomannan assay (11,12).

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号